Form 4: Moleculin Biotech CFO Receives Stock Grant
Insider Transaction (Form 4)
Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech, Inc., reported multiple transactions in common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 130,000 Common Stock on October 15, 2026; holds 435,673 after (Direct).
- Tax/exercise-price withholding: disposed of 30,485 Common Stock at $0.37 ($11,282) on October 15, 2026; holds 405,188 after (Direct).
- Grant/award: acquired 260,000 Stock Options (right to buy) on October 15, 2026; holds 1,287,717 after (Direct).
- Grant/award: acquired 260,000 Restricted Stock Units on October 15, 2026; holds 1,547,717 after (Direct).
- Option exercise/conversion: disposed of 130,000 Restricted Stock Units on October 15, 2026; holds 1,417,717 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jonathan P. Foster — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 130,000 | — | — | 435,673 |
| 2026-10-15 | Tax/exercise-price withholding | Common Stock | 30,485 | $0 | $11.3K | 405,188 |
| 2026-10-15 | Grant/award | Stock Options (right to buy) | 260,000 | — | — | 1,287,717 |
| 2026-10-15 | Grant/award | Restricted Stock Units | 260,000 | — | — | 1,547,717 |
| 2026-10-15 | Option exercise/conversion | Restricted Stock Units | 130,000 | — | — | 1,417,717 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (130,000 shares) |
| 2026-10-15 | Tax/exercise-price withholding (30,485 shares) |
| 2026-10-15 | Grant/award (260,000 shares) |
| 2026-10-15 | Grant/award (260,000 shares) |
| 2026-10-15 | Option exercise/conversion (130,000 shares) |
Keywords
insider transaction, Form 4, MBRX, Moleculin Biotech, Inc., neutral, Jonathan P. Foster
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.